Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
Identifieur interne : 002060 ( PubMed/Curation ); précédent : 002059; suivant : 002061Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
Auteurs : Marc P. Bonaca [Serbie] ; Deepak L. Bhatt [États-Unis] ; P Gabriel Steg [France] ; Robert F. Storey [Royaume-Uni] ; Marc Cohen [États-Unis] ; Kyungah Im [États-Unis] ; Ton Oude Ophuis [Pays-Bas] ; Andrej Budaj [Pologne] ; Shinya Goto [Japon] ; José L Pez-Send N [Espagne] ; Rafael Diaz [Argentine] ; Anthony Dalby [Afrique du Sud] ; Frans Van De Werf [Belgique] ; Diego Ardissino [Italie] ; Gilles Montalescot [France] ; Philip Aylward [Australie] ; Giulia Magnani [États-Unis] ; Eva C. Jensen [Suède] ; Peter Held [Suède] ; Eugene Braunwald [États-Unis] ; Marc S. Sabatine [États-Unis]Source :
- European heart journal [ 1522-9645 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Adénosine (administration et posologie), Adénosine (analogues et dérivés), Adénosine (effets indésirables), Antagonistes des récepteurs purinergiques P2Y (administration et posologie), Antagonistes des récepteurs purinergiques P2Y (effets indésirables), Calendrier d'administration des médicaments, Facteurs de risque, Femelle, Humains, Hémorragie (), Infarctus du myocarde (mortalité), Infarctus du myocarde (traitement médicamenteux), Ischémie myocardique (), Ischémie myocardique (mortalité), Mâle, Prévention secondaire, Résultat thérapeutique, Sujet âgé.
- MESH :
- administration et posologie : Adénosine, Antagonistes des récepteurs purinergiques P2Y.
- analogues et dérivés : Adénosine.
- effets indésirables : Adénosine, Antagonistes des récepteurs purinergiques P2Y.
- mortalité : Infarctus du myocarde, Ischémie myocardique.
- traitement médicamenteux : Infarctus du myocarde.
- Adulte d'âge moyen, Calendrier d'administration des médicaments, Facteurs de risque, Femelle, Humains, Hémorragie, Ischémie myocardique, Mâle, Prévention secondaire, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adenosine (administration & dosage), Adenosine (adverse effects), Adenosine (analogs & derivatives), Aged, Drug Administration Schedule, Female, Hemorrhage (chemically induced), Humans, Male, Middle Aged, Myocardial Infarction (drug therapy), Myocardial Infarction (mortality), Myocardial Ischemia (mortality), Myocardial Ischemia (prevention & control), Purinergic P2Y Receptor Antagonists (administration & dosage), Purinergic P2Y Receptor Antagonists (adverse effects), Risk Factors, Secondary Prevention, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Adenosine, Purinergic P2Y Receptor Antagonists.
- chemical , adverse effects : Adenosine, Purinergic P2Y Receptor Antagonists.
- chemical , analogs & derivatives : Adenosine.
- chemically induced : Hemorrhage.
- drug therapy : Myocardial Infarction.
- mortality : Myocardial Infarction, Myocardial Ischemia.
- prevention & control : Myocardial Ischemia.
- Aged, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Risk Factors, Secondary Prevention, Treatment Outcome.
Abstract
Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy.
DOI: 10.1093/eurheartj/ehv531
PubMed: 26491109
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002085
Links to Exploration step
pubmed:26491109Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.</title><author><name sortKey="Bonaca, Marc P" sort="Bonaca, Marc P" uniqKey="Bonaca M" first="Marc P" last="Bonaca">Marc P. Bonaca</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA mbonaca@partners.org.</nlm:affiliation><country wicri:rule="url">Serbie</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L" last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P Gabriel" last="Steg">P Gabriel Steg</name><affiliation wicri:level="1"><nlm:affiliation>Département de Cardiologie, Hôpital Bichat, Assistance Publique, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Cardiologie, Hôpital Bichat, Assistance Publique, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Storey, Robert F" sort="Storey, Robert F" uniqKey="Storey R" first="Robert F" last="Storey">Robert F. Storey</name><affiliation wicri:level="1"><nlm:affiliation>University of Sheffield, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Sheffield, Sheffield</wicri:regionArea></affiliation></author><author><name sortKey="Cohen, Marc" sort="Cohen, Marc" uniqKey="Cohen M" first="Marc" last="Cohen">Marc Cohen</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cardiovascular Division, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York</wicri:regionArea></affiliation></author><author><name sortKey="Im, Kyungah" sort="Im, Kyungah" uniqKey="Im K" first="Kyungah" last="Im">Kyungah Im</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Oude Ophuis, Ton" sort="Oude Ophuis, Ton" uniqKey="Oude Ophuis T" first="Ton" last="Oude Ophuis">Ton Oude Ophuis</name><affiliation wicri:level="1"><nlm:affiliation>CWZ Hospital, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>CWZ Hospital, Nijmegen</wicri:regionArea></affiliation></author><author><name sortKey="Budaj, Andrej" sort="Budaj, Andrej" uniqKey="Budaj A" first="Andrej" last="Budaj">Andrej Budaj</name><affiliation wicri:level="1"><nlm:affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Postgraduate Medical School, Grochowski Hospital, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Goto, Shinya" sort="Goto, Shinya" uniqKey="Goto S" first="Shinya" last="Goto">Shinya Goto</name><affiliation wicri:level="1"><nlm:affiliation>Tokai University School of Medicine, Institute of Medical Science, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Tokai University School of Medicine, Institute of Medical Science, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="L Pez Send N, Jose" sort="L Pez Send N, Jose" uniqKey="L Pez Send N J" first="José" last="L Pez-Send N">José L Pez-Send N</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario La Paz, Instituto de Investigación La PAZ, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario La Paz, Instituto de Investigación La PAZ, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name><affiliation wicri:level="1"><nlm:affiliation>ECLA (Estudios Clínicos Latino América), Rosario, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>ECLA (Estudios Clínicos Latino América), Rosario</wicri:regionArea></affiliation></author><author><name sortKey="Dalby, Anthony" sort="Dalby, Anthony" uniqKey="Dalby A" first="Anthony" last="Dalby">Anthony Dalby</name><affiliation wicri:level="1"><nlm:affiliation>Milpark Hospital, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Milpark Hospital, Johannesburg</wicri:regionArea></affiliation></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Cardiovascular Sciences, University of Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Ardissino, Diego" sort="Ardissino, Diego" uniqKey="Ardissino D" first="Diego" last="Ardissino">Diego Ardissino</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma</wicri:regionArea></affiliation></author><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47 boul de l'Hôpital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47 boul de l'Hôpital, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, Adelaide, South Australia</wicri:regionArea></affiliation></author><author><name sortKey="Magnani, Giulia" sort="Magnani, Giulia" uniqKey="Magnani G" first="Giulia" last="Magnani">Giulia Magnani</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Jensen, Eva C" sort="Jensen, Eva C" uniqKey="Jensen E" first="Eva C" last="Jensen">Eva C. Jensen</name><affiliation wicri:level="1"><nlm:affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>AstraZenecaAZ R&D, Molndal</wicri:regionArea></affiliation></author><author><name sortKey="Held, Peter" sort="Held, Peter" uniqKey="Held P" first="Peter" last="Held">Peter Held</name><affiliation wicri:level="1"><nlm:affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>AstraZenecaAZ R&D, Molndal</wicri:regionArea></affiliation></author><author><name sortKey="Braunwald, Eugene" sort="Braunwald, Eugene" uniqKey="Braunwald E" first="Eugene" last="Braunwald">Eugene Braunwald</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26491109</idno><idno type="pmid">26491109</idno><idno type="doi">10.1093/eurheartj/ehv531</idno><idno type="wicri:Area/PubMed/Corpus">002085</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002085</idno><idno type="wicri:Area/PubMed/Curation">002060</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002060</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.</title><author><name sortKey="Bonaca, Marc P" sort="Bonaca, Marc P" uniqKey="Bonaca M" first="Marc P" last="Bonaca">Marc P. Bonaca</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA mbonaca@partners.org.</nlm:affiliation><country wicri:rule="url">Serbie</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L" last="Bhatt">Deepak L. Bhatt</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Steg, P Gabriel" sort="Steg, P Gabriel" uniqKey="Steg P" first="P Gabriel" last="Steg">P Gabriel Steg</name><affiliation wicri:level="1"><nlm:affiliation>Département de Cardiologie, Hôpital Bichat, Assistance Publique, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de Cardiologie, Hôpital Bichat, Assistance Publique, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Storey, Robert F" sort="Storey, Robert F" uniqKey="Storey R" first="Robert F" last="Storey">Robert F. Storey</name><affiliation wicri:level="1"><nlm:affiliation>University of Sheffield, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Sheffield, Sheffield</wicri:regionArea></affiliation></author><author><name sortKey="Cohen, Marc" sort="Cohen, Marc" uniqKey="Cohen M" first="Marc" last="Cohen">Marc Cohen</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cardiovascular Division, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York</wicri:regionArea></affiliation></author><author><name sortKey="Im, Kyungah" sort="Im, Kyungah" uniqKey="Im K" first="Kyungah" last="Im">Kyungah Im</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Oude Ophuis, Ton" sort="Oude Ophuis, Ton" uniqKey="Oude Ophuis T" first="Ton" last="Oude Ophuis">Ton Oude Ophuis</name><affiliation wicri:level="1"><nlm:affiliation>CWZ Hospital, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>CWZ Hospital, Nijmegen</wicri:regionArea></affiliation></author><author><name sortKey="Budaj, Andrej" sort="Budaj, Andrej" uniqKey="Budaj A" first="Andrej" last="Budaj">Andrej Budaj</name><affiliation wicri:level="1"><nlm:affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Postgraduate Medical School, Grochowski Hospital, Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Goto, Shinya" sort="Goto, Shinya" uniqKey="Goto S" first="Shinya" last="Goto">Shinya Goto</name><affiliation wicri:level="1"><nlm:affiliation>Tokai University School of Medicine, Institute of Medical Science, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Tokai University School of Medicine, Institute of Medical Science, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="L Pez Send N, Jose" sort="L Pez Send N, Jose" uniqKey="L Pez Send N J" first="José" last="L Pez-Send N">José L Pez-Send N</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario La Paz, Instituto de Investigación La PAZ, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario La Paz, Instituto de Investigación La PAZ, Madrid</wicri:regionArea></affiliation></author><author><name sortKey="Diaz, Rafael" sort="Diaz, Rafael" uniqKey="Diaz R" first="Rafael" last="Diaz">Rafael Diaz</name><affiliation wicri:level="1"><nlm:affiliation>ECLA (Estudios Clínicos Latino América), Rosario, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>ECLA (Estudios Clínicos Latino América), Rosario</wicri:regionArea></affiliation></author><author><name sortKey="Dalby, Anthony" sort="Dalby, Anthony" uniqKey="Dalby A" first="Anthony" last="Dalby">Anthony Dalby</name><affiliation wicri:level="1"><nlm:affiliation>Milpark Hospital, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Milpark Hospital, Johannesburg</wicri:regionArea></affiliation></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Cardiovascular Sciences, University of Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Ardissino, Diego" sort="Ardissino, Diego" uniqKey="Ardissino D" first="Diego" last="Ardissino">Diego Ardissino</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma</wicri:regionArea></affiliation></author><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="1"><nlm:affiliation>Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47 boul de l'Hôpital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47 boul de l'Hôpital, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation wicri:level="1"><nlm:affiliation>Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, Adelaide, South Australia</wicri:regionArea></affiliation></author><author><name sortKey="Magnani, Giulia" sort="Magnani, Giulia" uniqKey="Magnani G" first="Giulia" last="Magnani">Giulia Magnani</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Jensen, Eva C" sort="Jensen, Eva C" uniqKey="Jensen E" first="Eva C" last="Jensen">Eva C. Jensen</name><affiliation wicri:level="1"><nlm:affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>AstraZenecaAZ R&D, Molndal</wicri:regionArea></affiliation></author><author><name sortKey="Held, Peter" sort="Held, Peter" uniqKey="Held P" first="Peter" last="Held">Peter Held</name><affiliation wicri:level="1"><nlm:affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>AstraZenecaAZ R&D, Molndal</wicri:regionArea></affiliation></author><author><name sortKey="Braunwald, Eugene" sort="Braunwald, Eugene" uniqKey="Braunwald E" first="Eugene" last="Braunwald">Eugene Braunwald</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author><author><name sortKey="Sabatine, Marc S" sort="Sabatine, Marc S" uniqKey="Sabatine M" first="Marc S" last="Sabatine">Marc S. Sabatine</name><affiliation wicri:level="1"><nlm:affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115</wicri:regionArea></affiliation></author></analytic><series><title level="j">European heart journal</title><idno type="eISSN">1522-9645</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (administration & dosage)</term><term>Adenosine (adverse effects)</term><term>Adenosine (analogs & derivatives)</term><term>Aged</term><term>Drug Administration Schedule</term><term>Female</term><term>Hemorrhage (chemically induced)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Myocardial Infarction (drug therapy)</term><term>Myocardial Infarction (mortality)</term><term>Myocardial Ischemia (mortality)</term><term>Myocardial Ischemia (prevention & control)</term><term>Purinergic P2Y Receptor Antagonists (administration & dosage)</term><term>Purinergic P2Y Receptor Antagonists (adverse effects)</term><term>Risk Factors</term><term>Secondary Prevention</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénosine (administration et posologie)</term><term>Adénosine (analogues et dérivés)</term><term>Adénosine (effets indésirables)</term><term>Antagonistes des récepteurs purinergiques P2Y (administration et posologie)</term><term>Antagonistes des récepteurs purinergiques P2Y (effets indésirables)</term><term>Calendrier d'administration des médicaments</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Hémorragie ()</term><term>Infarctus du myocarde (mortalité)</term><term>Infarctus du myocarde (traitement médicamenteux)</term><term>Ischémie myocardique ()</term><term>Ischémie myocardique (mortalité)</term><term>Mâle</term><term>Prévention secondaire</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine</term><term>Purinergic P2Y Receptor Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adenosine</term><term>Purinergic P2Y Receptor Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adénosine</term><term>Antagonistes des récepteurs purinergiques P2Y</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adénosine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Myocardial Infarction</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adénosine</term><term>Antagonistes des récepteurs purinergiques P2Y</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Myocardial Infarction</term><term>Myocardial Ischemia</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infarctus du myocarde</term><term>Ischémie myocardique</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Myocardial Ischemia</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infarctus du myocarde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Secondary Prevention</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Hémorragie</term><term>Ischémie myocardique</term><term>Mâle</term><term>Prévention secondaire</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26491109</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>08</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>14</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur. Heart J.</ISOAbbreviation></Journal><ArticleTitle>Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.</ArticleTitle><Pagination><MedlinePgn>1133-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehv531</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients in PEGASUS-TIMI 54 were categorized by time from last P2Y12 inhibitor (days: ≤30, >30-360, >360). The risk of MACE and the efficacy of ticagrelor were compared across categories. In the placebo arm, patients who more recently stopped P2Y12 inhibitor therapy had a greater number of risk factors but still had a higher risk of MACE after multivariable adjustment [≤30 days, hazard ratio (HR)adj 1.47, 95% confidence interval (CI) 1.12-1.93, P = 0.0051; 30 days-1 year, HRadj 1.28, 95% CI 0.98-1.67, P = 0.073] compared with those who stopped >1 year prior (P-trend = 0.0097). The benefit of ticagrelor depended on the time from last dose, with HRs (95% CI) for ticagrelor (pooled doses) vs. placebo of 0.73 (0.61-0.87), 0.86 (0.71-1.04), and 1.01 (0.80-1.27), respectively, by category (P-trend for interaction < 0.001). The benefit in those ≤30 days of stopping was similar regardless of time from MI (<2 years, HR 0.73, 95% CI 0.60-0.89 vs. ≥2 years, HR 0.71, 95% CI 0.50-1.00).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The benefit of ticagrelor for long-term secondary prevention in patients with prior MI and at least one additional risk factor appeared more marked in patients continuing on or re-starting after only a brief interruption of P2Y12 inhibition, when compared with patients who had proved themselves stable more than 2 years from their MI and off P2Y12 inhibitor therapy for more than a year. The increase in bleeding events with ticagrelor was similar regardless of this time interval. For clinicians considering a strategy of prolonged P2Y12 inhibitor therapy in high-risk patients, these data suggest greater benefit in the continuation of such therapy without interruption after MI, rather than re-initiating such therapy in patients who have remained stable for an extended period. Future analyses may help to clarify further the profile of post-MI patients most likely to benefit from uninterrupted dual antiplatelet therapy.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION INFORMATION" NlmCategory="BACKGROUND">http://www.clinicaltrials.gov NCT01225562.</AbstractText><CopyrightInformation>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonaca</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA mbonaca@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Deepak L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steg</LastName><ForeName>P Gabriel</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Département de Cardiologie, Hôpital Bichat, Assistance Publique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storey</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Newark Beth Israel Medical Center, Mount Sinai School of Medicine, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Kyungah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oude Ophuis</LastName><ForeName>Ton</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CWZ Hospital, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budaj</LastName><ForeName>Andrej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tokai University School of Medicine, Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Sendón</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Universitario La Paz, Instituto de Investigación La PAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ECLA (Estudios Clínicos Latino América), Rosario, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalby</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Milpark Hospital, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Werf</LastName><ForeName>Frans</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardissino</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montalescot</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut de Cardiologie, Pitié-Salpêtrière Hospital, 47 boul de l'Hôpital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aylward</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnani</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Eva C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AstraZenecaAZ R&D, Molndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunwald</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatine</LastName><ForeName>Marc S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>TIMI Study Group, Brigham and Women's Hospital, Heart & Vascular Center, 75 Francis Street, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01225562</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058921">Purinergic P2Y Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>GLH0314RVC</RegistryNumber><NameOfSubstance UI="C503700">Ticagrelor</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Heart J. 2016 Apr 7;37(14):1143-4</RefSource><PMID Version="1">26530109</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058921" MajorTopicYN="N">Purinergic P2Y Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiplatelet therapy</Keyword><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Ischaemic risk</Keyword><Keyword MajorTopicYN="N">P2Y12 inhibition</Keyword><Keyword MajorTopicYN="N">Platelet inhibition</Keyword><Keyword MajorTopicYN="N">Secondary prevention</Keyword><Keyword MajorTopicYN="N">Ticagrelor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26491109</ArticleId><ArticleId IdType="pii">ehv531</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehv531</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002060 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002060 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26491109
|texte= Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26491109" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |